4D Molecular Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Emeryville CA United States (2013)

Organization Overview

First Clinical Trial
2020
NCT04483440
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

4D, LLC | 4D Molecular Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (5)

4d-125 (1 trial)

4d-150 (1 trial)

4d-310 (2 trials)

4d-710 (1 trial)

aflibercept (zaltrap) (1 trial)

Drugs in Phase 1 Trials (1)

4d-110 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroideremia (Phase 1)

Fabry Disease (Phase 2)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 6